Logo image
Sign in
Back
Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy
Journal article   Open access   Peer reviewed

Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy

Candice Jamois, Ekaterina Gibiansky, Leonid Gibiansky, Vincent Buchheit, Denis Sahin, Guillaume Cartron, Robert Marcus, Wolfgang Hiddemann, John Seymour, Jonathan Strefford, …
British Journal of Clinical Pharmacology, Vol.85(7), pp.1495-1506
01/01/1970
DOI: https://doi.org/10.1111/bcp.13920
PMCID: PMC6595360
PMID: 30866056

Abstract

Monoclonal antibodies Oncology Pharmacokinetic-pharmacodynamic Pharmacokinetics Population analysis
Obinutuzumab (G) is a humanized type II, Fc-glycoengineered anti-CD20 monoclonal antibody used in various indications, including patients with previously untreated front-line follicular lymphoma. We investigated sources of variability in G exposure and association of progression-free survival (PFS) with average concentration over induction (CmeanIND ) in front-line follicular lymphoma patients treated with G plus chemotherapy (bendamustine, CHOP, or CVP) in the GALLIUM trial.
url
Find in HALView
url
https://doi.org/10.1111/bcp.13920View
Published (Version of record) Open

Metrics

1 Record Views

Details

Logo image